New England Journal of Medicine· 2019Q1
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
- 1,341citations
- Q1SCImago
- 2019year
Short summary
Anifrolumab, a type I interferon receptor antibody, achieved a significantly higher response rate (47.8% vs. 31.5%) in active SLE patients over 48 weeks compared to placebo, based on the BICLA composite endpoint.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Rheumatology
RheumatologyMedicine